Supplementary data: Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

dataset

posted on 2024-04-12, 13:52 authored by Jaesh Naik, Ryan Dillon, Matthew Massello, Lewis Ralph, Zhuo Yang

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia' published in the Journal of Comparative Effectiveness Research.

Appendix 1: RESTORE IMI-2 Eligibility Criteria
Appendix 2: US age- and sex-matched general population mortality (used in the long-term Markov model)
Appendix 3: Model parameters with uncertainty information
Appendix 4: Probabilistic Sensitivity Analysis: Cost-effectiveness acceptability curve
Appendix 5: Scenario analysis
Appendix 6: Indirect Evidence’s Effect on Model Results

Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenario’. Methods: An economic model was constructed to compare two strategies: continuation of empiric piperacillin/tazobactam (PIP/TAZ) versus early adjustment to IMI/REL. A decision tree was used to depict the hospitalization period, and a Markov model used to capture long-term outcomes. Results: IMI/REL generated more quality-adjusted life years than PIP/TAZ, at an increased cost per patient. The incremental cost–effectiveness ratio of $17,529 per QALY is below the typical US willingness-to-pay threshold. Conclusion: IMI/REL may represent a cost-effective treatment for payers and a valuable option for clinicians, when considered alongside patient risk factors, local epidemiology, and susceptibility data.